A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Active:	No
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT04026412
Trial Phases:	Phase III	Protocol IDs:	CA209-73L (primary) NCI-2019-08594 2019-001222-98
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT04026412

Summary

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent
chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab
in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.